- TRADE NAME: Qinlock (Deciphera Pharmaceuticals)
- INDICATIONS: Gastrointestinal stromal tumor
- CLASS: Tyrosine kinase inhibitor
- HALF-LIFE: 14.8 hours
- FDA APPROVAL DATE: 05/15/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers, CYP3A inhibitors, Itraconazole - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
